Apollon Formularies officially opens International Cancer and Chronic Pain Institute

Apollon Formularies PLC (AQSE:APOL) said it has officially opened its International Cancer and Chronic Pain Institute in the Jamaican capital of Kingston.

Receiving Jamaican and international medical patients, the new facility will provide complementary and alternative treatments for cancer patients, including the company’s own medical cannabis products.

Demand from overseas clients is such that the Institute will admit its second UK-based patient in the middle of this month.

As well as providing help and relief to cancer sufferers, doctors and researchers will also garner ‘invaluable patient data’ on Apollon’s cannabis formulations, the company said.

"Our International Cancer Institute is one of a kind and I am proud to see our hard work pay off,” said Paul Burke, chief executive of Apollon Formularies Jamaica.

“Following our remarkable 3D cell culture test results and the expansion of our production facility, this next step will help Apollon compete on a world-class level whilst providing our patients with the treatment and expert care needed."

< Back to News